INO News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

IN

Mkt Cap

$107.5M

Volume

1.97M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerPfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option.Zacks Investment Research · Oct 8, 2026

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.Zacks Investment Research · Sep 30, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

Bet on 4 Top-Ranked Stocks With Rising P/EThe article explores how stocks with rising P/E ratios paired with accelerating earnings growth can deliver strong returns. Using specific screening criteria focused on earnings momentum and price performance, the analysis identifies four stocks: H World Group Limited (HTHT), Inovio Pharmaceuticals (INO), Nouveau Monde Graphite (NMG), and Cogent Communications (CCOI) as potential outperformers with consistent price gains and strong earnings surprises.Zacks Investment Research · Sep 14, 2026

Bet on 5 Top-Ranked Stocks With Rising P/EThe article explores how rising P/E ratios, combined with accelerating earnings growth and sustained price momentum, can indicate strong investment opportunities. Five stocks meeting these criteria are highlighted: CuriosityStream (CURI), Inovio Pharmaceuticals (INO), GDS Holdings (GDS), Nouveau Monde Graphite (NMG), and Cogent Communications (CCOI). These companies demonstrate consistent price gains relative to the S&P 500 and positive earnings trends.Zacks Investment Research · Sep 3, 2026

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.GlobeNewswire Inc. · Jul 21, 2026

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.GlobeNewswire Inc. · Jul 13, 2026

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsightOver 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.GlobeNewswire Inc. · Jun 16, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INOPomerantz LLP has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers for alleged securities fraud. The lawsuit claims defendants made false statements about FDA approval prospects and manufacturing capabilities for their lead product INO-3107. The company delayed BLA submission by a year due to manufacturing issues with the CELLECTRA device, and the FDA rejected accelerated approval eligibility. Stock fell 24.45% on the December 2025 announcement.GlobeNewswire Inc. · Apr 7, 2026

DEADLINE ALERT for PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsLaw Offices of Howard G. Smith announced securities fraud class action lawsuits against three publicly-traded companies: Paysafe Limited (PSFE) for undisclosed business risks and overstated guidance, Inovio Pharmaceuticals (INO) for deficient manufacturing and overstated regulatory prospects, and Kyndryl Holdings (KD) for misstated financial statements and inadequate internal controls. Lead plaintiff deadlines range from April 7-13, 2026.GlobeNewswire Inc. · Apr 7, 2026

IN

INOInovio Pharmaceuticals, Inc.

INO

Pay with—

Available Balance0.00

Your PositionYou don't own any INO yet.

Related Tickers

Earnings